In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Micrus Corp.

Executive Summary

Micrus hopes to break into the underpenetrated market of minimally invasive treatments for cerebral aneurysms with a microcoil that has, it claims, performance characteristics that are superior to Target Therapeutics' Guglielmi Detachable Coil.

You may also be interested in...



Shades of BENESTENT in the Aneurysm World

UK investigators' recent decision to call an early halt to enrollment in a major study comparing neurosurgical clipping to endovascular coil treatment of ruptured cerebral aneurysms may signal a significant change of practice habits in a critical area of neurology. The findings, if they're as good as they appear to be, could do to surgical clipping and endovascular coils what the BENESTENT trials of the early 1990s did to promote stenting over balloon angioplasty in patients with coronary artery disease.

Lilly’s ‘High Quality’ Donanemab Data Supports Unrestricted Medicare Coverage, Firm Says

As FDA decision on Alzheimer’s product approaches, new paper outlines Lilly’s arguments for unfettered Medicare coverage for donanemab once it is approved.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

IV000988

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel